Literature DB >> 21156812

Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4.

Jyothi C Talakad1, Manish B Shah, Gregory S Walker, Cathie Xiang, James R Halpert, Deepak Dalvie.   

Abstract

A recent X-ray crystal structure of a rabbit cytochrome P450 2B4 (CYP2B4)-ticlopidine complex indicated that the compound could be modeled with either the thiophene or chlorophenyl group oriented toward the heme prosthetic group. Subsequent NMR relaxation and molecular docking studies suggested that orientation with the chlorophenyl ring closer to the heme was the preferred one. To evaluate the predictive value of these findings, the oxidation of ticlopidine by reconstituted CYP2B4 was studied and compared with CYP2B6, in which the thiophene portion of the molecule likely orients toward the heme. In vitro incubation of ticlopidine with both enzymes yielded the same set of metabolites: 7-hydroxyticlopidine (M1), 2-oxoticlopidine (M2), 5-(2-chlorobenzyl)thieno[3,2-c]pyridin-5-ium metabolite (M3), 5-(2-chlorobenzyl)thieno[3,2-c]pyridin-5-ium metabolite (M4), ticlopidine N-oxide (M5), and ticlopidine S-oxide dimer, a dimerization product of ticlopidine S-oxide (M6). The rates of metabolite formation deviated markedly from linearity with time, consistent with the known inactivation of CYP2B6 by ticlopidine. Fitting to a first-order equation yielded similar rate constants (k(obs)) for both enzymes. However, the amplitude (R(max)) of M1 and M6 formation was 4 to 5 times higher for CYP2B6 than CYP2B4, indicating a greater residence time of ticlopidine with its thiophene ring closer to heme in CYP2B6. In contrast, CYP2B4 formed M4 and M5 in more abundance than CYP2B6, indicating an alternate orientation. Overall, the results suggest that the preferential orientation of ticlopidine in the active site of CYP2B4 predicted by X-ray crystallography and NMR studies is unproductive and that ticlopidine likely reorients within CYP2B4 to a more productive mode.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156812      PMCID: PMC3061560          DOI: 10.1124/dmd.110.037101

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  39 in total

1.  Structures of cytochrome P450 2B4 complexed with the antiplatelet drugs ticlopidine and clopidogrel .

Authors:  Sean C Gay; Arthur G Roberts; Keiko Maekawa; Jyothi C Talakad; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Biochemistry       Date:  2010-09-15       Impact factor: 3.162

Review 2.  Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Authors:  Sean C Gay; Arthur G Roberts; James R Halpert
Journal:  Future Med Chem       Date:  2010-09       Impact factor: 3.808

3.  In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6.

Authors:  J W Ko; Z Desta; N V Soukhova; T Tracy; D A Flockhart
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

4.  Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19.

Authors:  N T Ha-Duong; S Dijols; A C Macherey; J A Goldstein; P M Dansette; D Mansuy
Journal:  Biochemistry       Date:  2001-10-09       Impact factor: 3.162

5.  Rational engineering of cytochromes P450 2B6 and 2B11 for enhanced stability: Insights into structural importance of residue 334.

Authors:  Jyothi C Talakad; P Ross Wilderman; Dmitri R Davydov; Santosh Kumar; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2009-11-26       Impact factor: 4.013

Review 6.  Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

Authors:  Nagy A Farid; Atsushi Kurihara; Steven A Wrighton
Journal:  J Clin Pharmacol       Date:  2009-11-30       Impact factor: 3.126

7.  Crystal structures of cytochrome P450 2B4 in complex with the inhibitor 1-biphenyl-4-methyl-1H-imidazole: ligand-induced structural response through alpha-helical repositioning.

Authors:  Sean C Gay; Ling Sun; Keiko Maekawa; James R Halpert; C David Stout
Journal:  Biochemistry       Date:  2009-06-09       Impact factor: 3.162

8.  Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution.

Authors:  Sean C Gay; Manish B Shah; Jyothi C Talakad; Keiko Maekawa; Arthur G Roberts; P Ross Wilderman; Ling Sun; Jane Y Yang; Stephanie C Huelga; Wen-Xu Hong; Qinghai Zhang; C David Stout; James R Halpert
Journal:  Mol Pharmacol       Date:  2010-01-08       Impact factor: 4.436

9.  Metabolism of ticlopidine in rats: identification of the main biliary metabolite as a glutathione conjugate of ticlopidine S-oxide.

Authors:  Shinji Shimizu; Ryo Atsumi; Tsunenori Nakazawa; Yuko Fujimaki; Kenichi Sudo; Osamu Okazaki
Journal:  Drug Metab Dispos       Date:  2009-06-18       Impact factor: 3.922

10.  tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance.

Authors:  Haoming Zhang; Hsia-lien Lin; Vyvyca J Walker; Djemel Hamdane; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-08-31       Impact factor: 4.436

View more
  8 in total

Review 1.  Plasticity of CYP2B enzymes: structural and solution biophysical methods.

Authors:  P Ross Wilderman; James R Halpert
Journal:  Curr Drug Metab       Date:  2012-02       Impact factor: 3.731

2.  Mechanism-based inactivation of human cytochrome P450 2B6 by clopidogrel: involvement of both covalent modification of cysteinyl residue 475 and loss of heme.

Authors:  Haoming Zhang; Hemali Amunugama; Sarah Ney; Nyemade Cooper; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2011-08-23       Impact factor: 4.436

3.  Halogen-π Interactions in the Cytochrome P450 Active Site: Structural Insights into Human CYP2B6 Substrate Selectivity.

Authors:  Manish B Shah; Jingbao Liu; Qinghai Zhang; C David Stout; James R Halpert
Journal:  ACS Chem Biol       Date:  2017-04-06       Impact factor: 5.100

4.  Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back.

Authors:  James R Halpert
Journal:  Drug Metab Dispos       Date:  2011-04-18       Impact factor: 3.922

5.  Differential oxidation of two thiophene-containing regioisomers to reactive metabolites by cytochrome P450 2C9.

Authors:  Peter M Rademacher; Caleb M Woods; Qingbiao Huang; Grazyna D Szklarz; Sidney D Nelson
Journal:  Chem Res Toxicol       Date:  2012-03-14       Impact factor: 3.739

6.  Use of Phenoxyaniline Analogues To Generate Biochemical Insights into the Interactio n of Polybrominated Diphenyl Ether with CYP2B Enzymes.

Authors:  Chao Chen; Jingbao Liu; James R Halpert; P Ross Wilderman
Journal:  Biochemistry       Date:  2017-12-19       Impact factor: 3.162

7.  A Pharmacokinetic and Metabolism Study of the TRPC6 Inhibitor SH045 in Mice by LC-MS/MS.

Authors:  Xiao-Ning Chai; Friedrich-Alexander Ludwig; Anne Müglitz; Yuanyuan Gong; Michael Schaefer; Ralf Regenthal; Ute Krügel
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923

8.  Inhibitory Effects of Trapping Agents of Sulfur Drug Reactive Intermediates against Major Human Cytochrome P450 Isoforms.

Authors:  Jasleen K Sodhi; Erlie Marie Delarosa; Jason S Halladay; James P Driscoll; Teresa Mulder; Patrick M Dansette; S Cyrus Khojasteh
Journal:  Int J Mol Sci       Date:  2017-07-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.